Skip to main content

Table 3 The marginal annual cost saving, cost - effectiveness and cost – benefit of SIF in Montreal using the Jacobs et al.[18] model

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada

Variables Annual cost of operation Sharing rate Marginal # of HIV averted Marginal # of HCV averted Marginal Marginal Marginal Marginal Marginal Marginal
HIV cost saved HCV cost saved cost-effectiveness ratio HCV cost-effectiveness ratio HIV cost-benefit ratio HCV cost-benefit ratio HIV
Post SIF $2,182,800 35% 14 84 $764,970 $769,212 $25,986 $155,914 1.35 1.35
Two SIF $2,182,800 28% 12 78 $343,860 $558,354 $27,985 $181,900 1.26 1.16
Three SIF $2,182,800 21% 6 33 -$919,470 -$1,023,081 $66,145 $363,800 0.53 0.57
Four SIF $2,182,800 18% 5 32 -$1,130,025 -$1,058,224 $38,463 $436,560 0.52 0.48
Five SIF $2,182,800 16% 6 34 -$1,200,540 -$987,938 $41,816 $363,800 0.55 0.58
Six SIF $2,182,800 13% 5 33 -$1,130,025 -$1,023,081 $66,145 $436,560 0.53 0.57
Seven SIF $2,182,800 10% 5 33 -$919,470 -$1,023,081 $66,145 $436,560 0.53 0.57
Average $2,182,800 7% 8 47 -$498,360 -$531,079 $46,442 $272,850 0.76 0.77